ICR | Cannabinoid company expands into oncology

Cannabinoid company expands into oncology

Oxford Cannabinoid Technologies Holdings (OCTP) – the company developing prescription cannabinoid medicines – is expanding its research and development plans into oncology. The decision comes after it identified a potential first in class immunotherapy agent for solid tumour treatment.

The oldest independent membership-led professional body for clinical researchers across the globe.